Cardiology

The Optometry Meeting in Anaheim

October 1-2, 2026

Jersey City Psychiatry

October 2-3, 2026

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Colorado Oncology Society

Kamel Abou Hussein, MD; Kit Y Lu, MD

Join Us at The Pathology Meeting in Las Vegas

October 5, 2026

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Wisconsin Association of Hematology and Oncology

Daniela A. Bota, MD, PhD; Benjamin Scheier, MD

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Montana/Wyoming

Syma Iqbal, MD; Shiven B. Patel, MD, MBA, FACP

26th Annual International Lung Cancer Congress

Roy S. Herbst, MD, PhD; Sandip Patel, MD, FASCO; Heather A. Wakelee, MD, FASCO

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Indiana Oncology Society

Kamel Abou Hussein, MD; Sushil Bhardwaj, MD, FACP

Tennessee Oncology Practice Society

1 Session is Available!

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | New Mexico Society of Clinical Oncology

Kamel Abou Hussein, MD; Kimberly Ku, MD

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Nevada Oncology Society

Sara A. Hurvitz, MD, FACP; Ajit K. Bisen, MD, MBA

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | The Arizona Clinical Oncology Society

Sara A. Hurvitz, MD, FACP; Milana Dolezal, MD, MSci

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

SriniVas R. Sadda, MD, FARVO; Mark R. Barakat, MD, FASRS; David A. Eichenbaum, MD, FASRS

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | Minnesota

Neil M. Iyengar, MD; Girish Kunapareddy, MD

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Louisiana Oncology Society

Geoffrey Ku, MD; Philip A. Haddad, MD, MPH, MHA, MS(HCI)

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Missouri Oncology Society

Geoffrey Ku, MD; Shiven B. Patel, MD, MBA, FACP

Depression, Apathy, and Anxiety in Parkinson Disease

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Iowa Oncology Society

Amy E. Armstrong, MD

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Empire State Hematology & Oncology Society

Wassim Mchayleh, MD, MBA, FACP; Yelda Nouri, MD

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | West Virginia

Neil M. Iyengar, MD; Swati Vishwanathan, MD

Community Oncology Connections™: Bridging Academic and Community Expertise in Evidence-Based Care for Desmoid Tumors | South Carolina Oncology Society

Tony Philip, MD, FACP, FASCO; Mrinal M. Gounder, MD

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Stephen C. Pflugfelder, MD; Cecelia Koetting, OD, FAAO, DipABO

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Stephen C. Pflugfelder, MD; Cecelia Koetting, OD, FAAO, DipABO

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Wisconsin Association of Hematology and Oncology

Virginia Kaklamani, MD, DSc; Girish Kunapareddy, MD

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Arkansas Association of Cancer Professionals

Amy E. Armstrong, MD; Anu Batra, MD

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | Wyoming State Oncology Society & Montana State Oncology Society

Sarah M. Tolaney, MD, MPH; Yelda Nouri, MD

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York

Lori A. Leslie, MD; Bachar Samra, MD

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Arkansas

Lori A. Leslie, MD; Alex Mejia, MD

IgAN Case Files: Real Conversations, Evolving Evidence

Gerald Bernard Appel, MD; Ellie Kelepouris, MD, FACP, FAHA

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Basil Williams, MD; Maura Di Nicola, MD

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | North Carolina Oncology Association

Daniela A. Bota, MD, PhD; Maya Hrachova, DO

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Indiana Oncology Society

Geoffrey Ku, MD; Girish Kunapareddy, MD

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | Rhode Island Oncology Society

Shiven Patel, MD, MBA, FACP; Sunnie S. Kim, MD

Montana State Oncology Society

1 Session is Available!

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

3 Things You Should Know About Enhancing Outcomes with Toric IOLs

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – North Carolina

Krish Patel, MD; Tara Graff, DO, MS

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Montana/Wyoming

Lori A. Leslie, MD; Jack W. Erter III, MD, MMHC

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Washington

Krish Patel, MD; Girish Kunapareddy, MD

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Tennessee

Krish Patel, MD; Premila Malhotra, MD

Clinical Consultations™: Tailoring Treatment for Cystic Fibrosis (CF) Across Life Stages and Evolving Health Needs

Elizabeth Burgener, MD; Leah A. Cohen, MD; William R. Hunt, MD, FAAP, FACP, FSSCI

SimulatEd™: Partnering for Precision – A Framework for Personalized Care Planning in Acute Lymphoblastic Leukemia

Jae Park, MD

Texas Society of Clinical Oncology

2 Sessions are Available!

Understanding and Overcoming Negative Preconceptions About MAOIs

9th Annual School of Nursing Oncology™

Beth Faiman, PhD, MSN, APN-BC, BMTCN, AOCN, FAAN, FAPO; Beth Sandy, MSN, CRNP, FAPO; Lindsay Adkins, MSN, FNP-BC, BMTCN; Jeneth Aquino, DNP, FNP-BC; Casey Gormley, MSN, FNP-C, AOCNP; Heather J. Jackson, PhD, FNP-BC; Kelsey Martin, AG-ACNP-BC, AOCNP; Nerina T. McDonald, PA-C; Lauren Verity Moore, DNP, MSN, AGACNP-BC; Faith A. Mutale, DNP, CRNP; Tiffany Richards, PhD, ANP-BC, AOCNP; Emily Skotte, DNP, MSN, ACNP-BC; Leslie Smith, DNP, RN, APRN-CNS, AOCNS, BMTCN; Saneese Stephen, PA-C, MPAS; Sara M. Tinsley-Vance, PhD, APRN, AOCN

MacTel Decoded: Rethinking Conventional Approaches With Novel Neuroprotective Strategies

Charles C. Wykoff MD, PhD; Diana V. Do, MD; Dante Pieramici, MD, FASRS; Jed H. Assam, MD

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

John Kitchens, MD; Michael W. Stewart, MD

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Nevada

Krish Patel, MD; Matthew Ulrickson, MD

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Kentucky

Lori A. Leslie, MD; Sushil Bhardwaj, MD, FACP

20th Annual New York Lung Cancers Symposium®

Balazs Halmos, MD, MS; Jamie Chaft, MD

ADA-SCID Chronicles: A Journey From Screening to Successful Outcomes

Morna Dorsey, MD, MS; Caroline Kuo, DPhil, MPhil

43rd Annual CFS®: Innovative Cancer Therapy for Tomorrow™

Benjamin P. Levy, MD; John O. Mascarenhas, MD; Tiffany A. Traina, MD, FASCO

Precision in Practice: Advancing Prostate Cancer Care With PSMA-Directed Radioligand Therapy

Scott T. Tagawa, MD, MS, FASCO, FACP; Himisha Beltran, MD; Neeta Pandit-Taskar, MD, MBA

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Rutika Mehta, MD, MPH

Navigating the Adverse Event Landscape in HER2+ GEA Therapy

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Geoffery Ku, MD; Shruti Patel, MD

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA, FASCO; Girish Dhall, MD

ISGIO 2025: Pancreatic and Neuroendocrine Tumors

Laura Dawson, MD, FRCPC, FASTRO; Thorvardur R. Halfdanarson, MD; Eileen M. O’Reilly, MD, FASCO; Scott Paulson, MD; Omair A. Shariq, MD, PhD; Aatur D. Singhi, MD, PhD; Alice C. Wei, MD, CM, MSc, FRCSC, FACS

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Oncology Town Hall: Shaping the Future of ALL Treatment Through Innovation in T-Cell Therapies

Claire Roddie, MD, PhD; Elias Jabbour, MD; Hagop Kantarjian, MD

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

ISGIO 2025: Advanced-Stage Colorectal Cancer

Cody Eslinger, MD, MS; Christopher Lieu, MD; Eric D. Miller, MD, PhD; Michael J. Overman, MD; Christina S. Wu, MD, MB, BCh

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Shubham Pant, MD, MBBS; Alison Schram, MD; Helena Yu, MD

Screening for Type 1 Diabetes and Delaying Its Onset—An Innovative View

Jennifer D. Goldman, PharmD, RPh, CDCES, BC-ADM, FCCP; Robert Busch, MD; Conan Tu, MD, MBA, DACD, BC-ADM; Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCES

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - NYC Metro

Deep Parikh, MD

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

Millie Das, MD; Wade Iams, MD, MSCI; Ruham Nasany, MD

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

Shazia Nakhoda, MD; Shruti Gupta, MD, MPH; Anitha Varghese, MSN, APRN, AGPCNP-C

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis

Mile Brujic, OD, FAAO; Pierce Kenworthy, OD, FAAO; Blair Lonsberry, MS, OD, MEd, FAAO

The Presbyopia-Correcting and Toric IOL Playbook: Game-Changing Surgical Strategies to Enhance Patient Outcomes

Uday Devgan, MD, FACS, FRCS

Burst CME™: Burden of Sickle Cell Disease

Matthew Heeney, MD; Biree Andemariam, MD

Burst CME™: Optimal Management of Complications of Sickle Cell Disease

Matthew Heeney, MD; Deepika S, Darbari, MD

Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis

Abigail Schwaede, MD; Alexis Lizarraga, MD, MS

Empowering HIV Management: Evidence-Based Prevention and Treatment Strategies

Onyema Ogbuagu, MD, FACP, FIDSA

Cases and Conversations™: Navigating CKD and Heart Failure in T1D and T2D—Applying the Latest Guidelines and Evidence

Stephen J Greene, MD; Anuradha Lala-Trindade, MD

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Hope S. Rugo, MD; Alison K. Conlin, MD; Marleen Kok, MD, PhD; Heather McArthur, MD, MPH

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Sara A. Hurvitz, MD, FACP; Rena Callahan, MD; Michelle Melisko, MD; Paolo Tarantino, MD, PhD

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

James F. Howard Jr, MD, FAAN; Tuan Vu, MD

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Seth A. Wander, MD, PhD; Marla D. Lipsyc-Sharf, MD

From Gene to Gut: Understanding TL1A’s Function in IBD Evolution

Jordan E. Axelrad, MD, MPH, FACG

The Rise of Novel HER2-Targeting Therapies in GEA: Mechanisms and Clinical Data

Rahul Gosain, MD, MBA; Rohit Gosain, MD

Advances in™: Lipoprotein(a) as a Target for ASCVD Risk Reduction – Updates for Clinical Practice

Pam R. Taub, MD, FACC, FASPC; Payal Kohli, MD, FACC

Burst CME™ in Gaucher Disease: Patient Evaluation and Management

Steven Fein, MD

Cases & Conversations™: Unmasking Epithelioid Sarcoma – Enhancing Early Diagnosis and Multidisciplinary Care

Mark Agulnik, MD; Mrinal M. Gounder, MD; Sandra D’Angelo, MD; Sujana Movva, MD

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

Medical Crossfire®: Experts Debate the Hottest Topics in AML – FLT3, IDH1/2, KMT2Ar, NPM1, Secondary AML, Maintenance, Novel Combinations, and Emerging Therapies

Naval Daver, MD; Daniel A. Pollyea, MD; Gail J. Roboz, MD; Amer Zeidan, MBBS, MHS

PER® Tumor Board: Charting a New Course in the Treatment of Newly Diagnosed Multiple Myeloma

Ajai Chari, MD; Maria-Victoria Mateos, MD, PhD; Mohamad Mohty, MD, PhD

Real-World Insights on Advances in the Management of Myeloproliferative Neoplasms: How the Experts Apply the Latest Developments to Clinical Practice

Naveen Pemmaraju, MD; Shannon Elf, PhD; Angela Fleischman, MD, PhD; Bethan Psaila, MD

Advances in ALL Management Across the Patient Spectrum: Integrating Innovation and Precision Care

Elias Jabbour, MD; Hagop Kantarjian, MD; Aaron Logan, MD, PhD, MPhil; Rob Pieters, MD, PhD; Claire Roddie, MD, PhD

SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer

Rachel N. Grisham, MD

Module 4: Breast Surgery (2025)

Eleftherios (Terry) Mamounas, MD, MPH, FACS; Michael Alvarado, MD, MS; Puneet Singh, MD, MS, FACS, FSSO, CMQ

Module 5: Breast Radiation Therapy (2025)

Douglas W. Arthur, MD, FABS, FASTRO; Eleanor E. Harris, MD, FASTRO; Kathleen Horst, MD

Module 3: Pathology And Biomarkers (2025)

Joyce O’Shaughnessy, MD; Sunil S. Badve, MD, FRCPath; Claudine Isaacs, MD; Michael F. Press, MD, PhD

Module 6: Adjuvant/Neoadjuvant Chemotherapy and Endocrine Therapy (2025)

Joyce O’Shaughnessy, MD; William J. Gradishar, MD, FASCO, FACP; N. Lynn Henry, MD, PhD, FASCO; Kevin Kalinsky, MD, MS; Joseph A. Sparano, MD; Sara Tolaney, MD, MPH

Module 1: Breast Carcinogenesis & Management of High-Risk Disease (2025)

Joyce O’Shaughnessy, MD; Carol Fabian, MD; Rachel Freedman, MD, MPH; Anne Grabenstetter, MD; Claudine Isaacs, MD; Pedram Razavi, MD, PhD

Module 7: Systemic Treatment Of Advanced/Metastatic Disease (2025)

William J. Gradishar, MD, FASCO, FACP; Ting Bao, MD, MS; Jennifer A. Ligibel, MD; Filipa Lynce, MD; Ruth O’Regan, MD, MSc

Module 2: Breast Imaging (2025)

Joyce O’Shaughnessy, MD; Connie Lehman, MD, PhD, FACR; David M. Schuster, MD, FACR

Module 8: Organ-Targeted Treatment of Metastatic Disease (2025)

Joyce O’Shaughnessy, MD; Michelle Melisko, MD; Beverly Moy, MD, MPH

Module 9: Toxicity Management And Survivorship Considerations (2025)

Joyce O’Shaughnessy, MD; Laura Huppert, MD; Michelle Melisko, MD; Michelle Mollica, PhD, MPH, RN, OCN; Ann H. Partridge, MD, MPH

Tumor Board™: Navigating a New Era of Innovation and Expanding Options in NMIBC

Archan Khandekar, MD; Wassim Kassouf, MD, CM, FRCSC; Jen-Jane Liu, MD

“D” is for Diagnosis: Decoding a Difficult Thoracic Malignancy—Piecing Together a Rare Diagnosis, Preparing for Tomorrow’s Treatments

Aakash Desai, MD, MPH; Ibiayi Dagogo-Jack, MD, FASCO; Patrick Forde, MD, PhD

Combination Approaches in PD-L1–Positive mTNBC: Practice-Changing Frontline Evidence

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Sherene Loi, MMBS (Hons), FRACP, PhD, FAHMS

First-Line ADC Monotherapy in mTNBC: Addressing Unmet Needs in Immunotherapy-Ineligible Populations

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Adam Brufsky, MD, PhD

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Gus Alva, MD, DFAPA; Erin Crown, MHS, PA-C

Decoding HER2 Alterations in GEA: Best Practices for Testing and Treatment

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Rondell P. Graham, MBBS; Tanios S. Bekaii-Saab, MD

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Jordan Axelrad, MD, MPH, FACG, FCCF; Jessica R. Allegretti, MD, MPH; Florian Rieder, MD

(CPE Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

Shifting the Paradigm in Small Cell Lung Cancer: Targeting Tumor Biology to Transform Patient Outcomes

Charles M. Rudin, MD, PhD; Alex A. Adjei, MD, PhD; Millie Das, MD

Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC

Narjust Florez, MD, FASCO; David P. Carbone, MD, PhD; Edward B. Garon, MD, MS

Current and Future Directions in Precision-Based ALL Therapy

Elias Jabbour, MD; Hagop M. Kantarjian, MD; Aaron C. Logan, MD, PhD, MPhil

From Molecular Insights to Clinical Impact: Translating the Latest Advances in Menin Inhibitors Into Practice

Naval G. Daver, MD; Amir Fathi, MD; Guillermo Garcia-Manero, MD; Aditi Shastri, MD

(CME Track) Medical Crossfire®: Menin Inhibitors in AML—Dissecting the Data to Define the Role

Naval Daver, MD; Courtney DiNardo, MD; Eunice Wang, MD

Medical Crossfire®: Redefining Frontline and Maintenance Strategies in HER2+ Metastatic Breast Cancer

Joyce O’Shaughnessy, MD; Reshma L. Mahtani, DO; Heather McArthur, MD, MPH; Paolo Tarantino, MD, PhD

Expanding Options, Evolving Challenges in Advanced HR+/HER2– Breast Cancer: How Experts Apply the Latest Data

Kevin Kalinsky, MD, MS; Adam Brufsky, MD, PhD; Kelly Elizabeth McCann, MD, PhD; Sara Nunnery, MD, MSCI

New Precision Strategies for HER2+ GEA: Interpreting New Data to Inform Clinical Practice

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Sunnie Kim, MD; Samuel L. Cytryn, MD

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

Ashish M. Kamat, MD, MBBS; Katie S. Murray, DO, MS; Thomas Powles, MD, MBBS, MRCP

Medical Crossfire®: Optimizing 𝘌𝘚𝘙1 Mutation Detection and Next-Generation Endocrine Therapy Integration in HR+/HER2– Breast Cancer

VK Gadi, MD, PhD; Neil M. Iyengar, MD; Heather McArthur, MD, MPH

Show Me the Data®: How Today’s Evidence Is Shaping Tomorrow’s Management and Prophylaxis of Chronic GVHD

Carrie L. Kitko, MD; Miguel-Angel Perales, MD; Amandeep Salhotra, MD

Coffee Talk: Charting New Pathways with HER2 and TROP2 Therapies – From Early to Advanced Breast Cancer

Hope S. Rugo, MD, FASCO; Paolo Tarantino, MD, PhD; Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS

Show Me the Data™: Translating Clinical and Practice-Based Evidence on Oral SERDs Into Everyday Care for HR+/HER2– Metastatic Breast Cancer

Reshma L. Mahtani, DO; Kamel Abou Hussein, MD; Irene Kang, MD

(COPE Track) Embracing the Interventional Glaucoma Mindset: A Paradigm Shift in Contemporary Glaucoma Management

Mary Qiu, MD; Paul Singh, MD; Danica J. Marrelli, OD, FAAO

Facilitating Precision Pathways: Surgical Considerations in Breast Cancer for Tackling Barriers to Genetic Testing and Targeted Therapies

Patrick I. Borgen, MD; Don S. Dizon, MD, FACP, FASCO; Kevin S. Hughes, MD, FACS; Banu Arun, MD, FASCO

(CME Track) Embracing the Interventional Glaucoma Mindset: A Paradigm Shift in Contemporary Glaucoma Management

Mary Qiu, MD; Paul Singh, MD; Danica J. Marrelli, OD, FAAO

Tying the Threads: Screening, Referrals, and Optimized Treatments in MASLD/MASH

Nancy Reau, MD; Conan Tu, MD; Sonal Kumar, MD, MPH

(CME Track) Reducing Treatment Burden in Retinal Disease Care With Extended-Duration Anti-VEGF Therapies

John Kitchens, MD

How Do I Identify MOGAD? Improving Outcomes Through Early Identification of Patients

Michael Levy, MD, PhD; Jeffrey L. Bennett, MD, PhD; Eoin P. Flanagan, MB, BCh

(COPE Track) Emerging Therapeutic Advancements in Dry Eye Disease Management

Rahul Tonk, MD; Jade Coats, OD, FAAO; Aaleya Koreishi, MD; Zeba Syed, MD

(COPE Track) Next-Generation Solutions for nAMD and DME: Bridging Evidence and Practice Gaps in Disease Management

Murtaza K. Adam, MD, FASRS; Deepak Sambhara, MD, FASRS; Betty Zhang, OD

(CME Track) Cutting-Edge Care in Neovascular Retinal Disease: Expert Approaches to Selection and Interval Extension

Geeta Lalwani, MD; Alla Goldberg, MD; Elite Bor-Shavit, MD

(CPE Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

Shazia Nakhoda, MD; Shruti Gupta, MD, MPH; Anitha Varghese, MSN, APRN, AGPCNP-C

Community Practice Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer

Neil M. Iyengar, MD; Sara M. Tolaney, MD, MPH

Burst CME Expert Illustrations & Commentaries™: Breaking Down DLL3-Targeting Immune Cell Effector Agents in SCLC

Jacob Sands, MD; Anne Chiang, MD, PhD

Publication Review: Defining On-Treatment Remission in Plaque Psoriasis

April W. Armstrong, MD, MPH; Tina Bhutani-Jacques MD

Virtual Hot Seat: How the Experts Target the PI3K/AKT/mTOR Pathway in HR+/HER2– Metastatic Breast Cancer

Rebecca Shatsky, MD; Maxwell Roger Lloyd, MD; Sarah Sammons, MD; Sherry Shen, MD

OncoBytes Adaptive Learning Pathways: Personalizing Treatment Plans to Optimize Adjuvant Therapy in Early-Stage HR+/HER2- Breast Cancer

Joyce O’Shaughnessy, MD; Virginia Kaklamani, MD, DSc; Seth A. Wander, MD, PhD

Medical Crossfire®: Translating Risk into Action—Redefining Adjuvant Strategies for Early HR+/HER2– Breast Cancer

Ann H. Partridge, MD, MPH; William J. Gradishar, MD, FASCO, FACP; Saranya Chumsri, MD

(CME Track) Next-Generation Solutions for nAMD and DME: Bridging Evidence and Practice Gaps in Disease Management

Murtaza K. Adam, MD, FASRS; Deepak Sambhara, MD, FASRS; Betty Zhang, OD

Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer

Sanja Dacic, MD, PhD; Soo-Ryum (Stewart) Yang, MD; Isabel Preeshagul, DO, MBS